A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effectsof SOtagLiflozin on Clinical Outcomes in HemOdynamIcally STable Patients with Type 2 Diabetes POSTWorsening Heart Failure

Medicine & Life Sciences

1. (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol 100%
2. Multicenter Studies 42%
3. Type 2 Diabetes Mellitus 37%
4. Heart Failure 36%
5. Placebos 34%